Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Anaesthesia is expressed as reversible state of unconsciousness, lack of pain, loss of memory and muscle relaxation. It is most associated with being placed in unconscious state for surgical procedures. On other hand it may give relief to individual who want to avoid pain of surgery, some risk related to induced anaesthetic condition can create fear in others mind. The most common side effects of anaesthesia are nausea and vomiting. The risk of anaesthesia is increases by the factors like smoking, obstructive sleep apnea, high blood pressure, obesity, diabetes, heart or lung associated medical condition, history of heavy alcohol use, drug allergies and history of adverse reaction with anaesthesia.
The United States general anaesthetic drug market is witnessing lucrative growth during forecast period 2021-2027. As aging population is growing more peoples needs medical care which is gaining attention of United States general anaesthetic drug market. The dynamic factors like increasing rate of surgical procedures such as cardiac, orthopaedic, general surgeries and other is propelling the market growth of United States general anaesthetic drug market. Surgical complexities and patient safety expectations is also refuelling the market growth of United States general anaesthetic drug market. The technological advancements in drug delivery devices is also elevating the market growth of United States general anaesthesia drug market. However, high cost of procedures and branded drugs is restraining the market growth of United States general anaesthetic drug market.
The exclusive COVID-19 impact analysis report by Axiom MRC provides a 3600 analysis of micro and macro-economic factors on the general anaesthetic drug market. In addition, complete analysis of changes on general anaesthetic drug expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on United States economies, international trade, business investments, GDP and marketing strategies of key players present in the market. There is slight slow growth of general anaesthetic drug market is experienced during the COVID-19 situation as there is several restraining factors like mismatch between demand and supply due to complete shutdown in many countries which hampered the transportation of general anaesthetic drugs. The several surgical procedures are post ponded during the time of COVID-19 pandemic. However, activities are resuming and all the pending surgeries are being held nowadays. The market acquired its original state and witnessing rapid growth during the forecast period 2021-2027.
The United States general anaesthetic drug market is categorised by drug molecule, route of administration and end user.
Drug Molecules like isoflurane, desflurane, sevoflurane, ketamine, thiopental, opioids, propofol and other are comprised in the United States general anaesthetic drug molecules. In which opioids is also contributing in the market growth of United States general anaesthetic drug market. Opioid have wide range applications in medicines since decades. They are specially used for treatment of pain and anaesthesia adjuvants or primary anaesthetic agent used in operative procedures. FDA approved the use of opioids during almost every surgery which comprised of induction of pre-induction for chronic pain condition, induction of anaesthesia and maintenance along with reduce immediate post-operative pain and minimize agitations.
Route of administrations like intravenous and inhalational are comprised in the United States general anaesthetic drug market. In which intravenous route is estimated to dominate the market in 2020. The intravenous anaesthesia provides high brain relaxation, maintained a lower ICP as well as better haemodynamic as compared with inhalational anaesthesia. Conversely, inhalational anaesthetic drugs works by suppressing effects on brain metabolism and cerebral blood flow similar to intravenous anaesthetic. Additionally, inhalational anaesthetic also causes vasodilation in the brain.
End users like hospitals, speciality clinics and ambulatory surgical centres are comprised in United States general anaesthetic drug market. In which hospitals is expected to dominate the market in 2020. The rising events of surgical procedures of cardiac, cancer, orthopaedic and other are elevating growth of market. The adoption of technically advanced healthcare equipment is also boosting the market growth of market. The rising initiative by government for reimbursement of healthcare costs is also propelling the market growth of United States general anaesthetic drug market.
The major key players in general anaesthetic drug market are Baxter International Inc. (Us), Hikma Pharmaceuticals Plc (Uk), Pfizer Inc. (Us), Piramal Enterprises Limited (India), Abbvie (Us), Fresenius Se & Co. Kgaa (Germany), Par Pharmaceutical (Us), Teva Pharmaceuticals (Israel), Viatris/Mylan (Us), Novartis Ag (Us), Abbott Laboratories (Us), Astrazeneca Plc (Us), F. Hoffmann-La Roche (Switzerland), Glaxosmithkline Plc (Uk), Gilead Sciences Inc. (Us), Bayer Ag (Germany), Merck & Co. Inc. (Germany), Sanofi (France), Heritage Pharmaceuticals Inc. (Us), Akorn (Us) and Apotex (Canada) among other are analysed.
August 2020: Fresenius Kabi introduced their first medication comprising smart label implanted with radio-frequency identification technology. The first RFID smart labelled product, Diprivan (propofol) 200mg per 20mL (10mg per mL) injectables Emulsion, USP, was introduced in the US
July 2020: The Acacia Pharma a group of PLC, granted U.S. FDA approval for BYFAVO (remimazolam) injection which is used for induction and maintenance of procedural sedation in adults undergoing procedures which lasts up to 30 minutes or less.
May 2020: The Hikma Pharmaceutical PLC, a multinational pharmaceutical company, announced their propofol injectable emulsion, USP. In various vials of 20ml, 50ml, 100ml in United States.
January 2020: Novartis AG acquired Aspen’s Japanese operations focused on generics and off-patent medicines.
The study comprised of general anaesthetic drug market. In which study analysed the various segments of the market. The general anaesthetic drug market is bifurcated by drug molecule, route of administration and end users. The study also comprised of dominating segment of the market. In the study it is profound that the drug molecule segment is dominated by propofol. Likewise, route of administration is dominated by intravenous route and end user segment is dominated by hospitals. The study also comprised of impact on COVID-19 on the general anaesthetic drug market and it conclude that there is slight slow growth of general anaesthetic drug market is experienced during the COVID-19 situation as there is several restraining factors like mismatch between demand and supply due to complete shutdown in many countries which hampered the transportation of general anaesthetic drugs. The several surgical procedures are post ponded during the time of COVID-19 pandemic. However, activities are resuming and all the pending surgeries are being held nowadays. The market acquired its original state and witnessing rapid growth during the forecast period 2021-2027. The study also imparts the major key players operating in the regions.
Why to buy this report
